Small-molecule CSF1R kinase inhibitors; review of patents 2015-present

References

• Chen X, Liu H, Focia PJ, et al. Structure of macrophage colony stimulating factor bound to FMS: diverse signalling assemblies of class III receptor tyrosine kinases. Proc Natl Acad Sci USA. 2008;105:18267–18272.
   PubMed Web of Science ®Google Scholar
• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–1134.
   PubMed Web of Science ®Google Scholar
• Hume DA, Irvine KM, Pridans C. The mononuclear phagocyte system: the relationship between monocytes and macrophages. Trends Immunol. 2019;40:98–112.
   PubMed Web of Science ®Google Scholar
• DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369–382.
   PubMed Web of Science ®Google Scholar
• Brioschi S, Zhou Y, Colonna M. Brain parenchymal and extraparenchymal macrophages in development, homeostasis, and disease. J Immunol. 2020;204:294–305.
   PubMed Web of Science ®Google Scholar
• Doig TN, Hume DA, Theocharidis T, et al. Coexpression analysis of large cancer datasets provides insight into the cellular phenotypes of the tumour microenvironment. BMC Genomics. 2013;14:469.
   PubMed Web of Science ®Google Scholar
• Hume DA, Caruso M, Ferrari-Cestari M, et al. Phenotypic impacts of CSF1R deficiencies in humans and model organisms. J Leukoc Biol. 2020;107(2):205–219.
   PubMed Web of Science ®Google Scholar
• Wu P, Nielsen TE, Clausen MH. FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci. 2015;36(7):422–439.
   PubMed Web of Science ®Google Scholar
• Walter M, Lucet IS, Patel O, et al. The 2.7 a crystal structure of the autoinhibited human c-Fms kinase domain. J Mol Biol. 2007;367:839–847.
   PubMed Web of Science ®Google Scholar
• Conway JG, McDonald B, Parhamet J, et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA. 2005;102:16078–16083.
   PubMed Web of Science ®Google Scholar
• Moon H-G, Kim S-J, Lee MK, et al. Colony-stimulating factor 1 and its receptor are new potential therapeutic targets for allergic asthma. Allergy (Oxford, UK). 2020;75:357–369.
   Google Scholar
• Neal ML, Fleming SM, Budge KM, et al. Pharmacological inhibition of CSF1R by GW2580 reduces microglial proliferation and is protective against neuroinflammation and dopaminergic neurodegeneration. FASEB J. 2020;34:1679–1694.
   PubMed Web of Science ®Google Scholar
• Farah S, Doloff JC, Muller P, et al. Long-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulations. Nat Mater. 2019;18:892–904.
   PubMed Web of Science ®Google Scholar
• Martinez-Muriana A, Mancuso R, Francos-Quijorna I, et al. CSF1R and invasion of macrophages into peripheral nerves. Sci Rep. 2016;6:25663.
   PubMed Web of Science ®Google Scholar
• Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264–1272.
   PubMed Web of Science ®Google Scholar
• Ikegashira K, Ikenogami T, Yamasaki T, et al. Discovery of a novel azetidine scaffold for colony stimulating factor-1 receptor (CSF-1R) type II inhibitors by the use of docking models. Bioorg Med Chem Lett. 2019;29:115–118.
   PubMedGoogle Scholar
• Ikegashira K, Ikenogami T, Yamasaki T, et al. Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) type II to lead to the clinical candidate JTE-952. Bioorg Med Chem Lett. 2019;29:873–877.
   PubMed Web of Science ®Google Scholar
• Uesato N, Miyagawa N, Inagaki K, et al. Pharmacological properties of JTE-952, an orally available and selective colony stimulating factor 1 receptor kinase inhibitor. Biol Pharm Bull. 2020;43(2):325–333.
   PubMed Web of Science ®Google Scholar
• Meyers MJ, Pelc M, Kamtekar S, et al. Structure-based drug design enables conversion of a DFG-in binding CSF-1R kinase inhibitor to a DFG-out binding mode. Bioorg Med Chem Lett. 2010;20:1543–1547.
   PubMed Web of Science ®Google Scholar
• Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 2008;105:3041–3046.
   PubMed Web of Science ®Google Scholar
• Zhang C, Ibrahim PN, Zhang J, et al. Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci USA. 2013;110:5689–5694.
   PubMed Web of Science ®Google Scholar
• Butowski N, Colman H, De Groot JF, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy foundation early phase clinical trials consortium phase II study. Neuro-oncol. 2016;18:557–564.
   PubMed Web of Science ®Google Scholar
• Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394:478–487.
   PubMed Web of Science ®Google Scholar
• Lamb YN. Pexidartinib: first approval. Drugs. 2019;79:1805–1812.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shan S, Li Z-B, et al. CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency. Cancer Sci. 2017;108:469–477.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Fu C, Kong Y, et al. Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models. Anticancer Drugs. 2019;30:909–916.
   PubMed Web of Science ®Google Scholar
• Ohno H, Kubo K, Murooka H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006;5:2634–2643.
   PubMed Web of Science ®Google Scholar
• Illig CR, Manthey CL, Wallet MJ, et al. Optimization of a potent class of arylamide colony-stimulating factor-1 receptor inhibitors leading to anti-inflammatory clinical candidate 4-cyano-N-[2-(1-cyclohexen-1-yl)-4-[1-[(dimethylamino)acetyl]-4-piperidinyl]phenyl]-1H-imidazole-2-carboxamide (JNJ-28312141). J Med Chem. 2011;54:7860–7883.
   PubMed Web of Science ®Google Scholar
• Coniglio S, Miller I, Symons M, et al. Coculture assays to study macrophage and microglia stimulation of glioblastoma invasion. J Vis Exp. 2016;116:e53990/1-e53990/8.
   Google Scholar
• Manthey CL, Johnson DL, Illig CR, et al. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia. Mol Cancer Ther. 2009;8:3151–3161.
   PubMed Web of Science ®Google Scholar
• von Tresckow B, Morschhauser F, Ribrag V, et al. An open-label, multicenter, phase I/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma. Clin Cancer Res. 2015;21:1843–1850.
   PubMed Web of Science ®Google Scholar
• Wang T, Papoutsi M, Wiesmann M. Investigation of correlation among safety biomarkers in serum, histopathological examination, and toxicogenomics. Int J Toxicol. 2011;30:300–312.
   PubMed Web of Science ®Google Scholar
• Krauser JA, Jin Y, Walles M, et al. Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite. Xenobiotica. 2015;45:107–123.
   PubMed Web of Science ®Google Scholar
• Jones P, Czako B, Burke JP, et al.; Tesaro. Compounds. WO 2018/081276 A1. 2018 Apr 3.
   Google Scholar
• Peng X, Hou P, Chen Y, et al. Preclinical evaluation of 3D185, a novel potent inhibitor of FGFR1/2/3 and CSF-1R, in FGFR-dependent and macrophage-dominant cancer models. J Exp Clin Cancer Res. 2019;38:372.
   PubMed Web of Science ®Google Scholar
• Liu Y-Q, Wang Y-N, Lu X-Y. Identification of compound D2923 as a novel anti-tumor agent targeting CSF1R. Acta Pharm Sin. 2018;39:1768–1776.
   PubMed Web of Science ®Google Scholar
• Xun Q, Zhang Z, Luo J, et al. Design, synthesis, and structure–activity relationship study of 2-oxo-3,4-dihydropyrimido[4,5-d]pyrimidines as new colony stimulating factor 1 receptor (CSF1R) kinase inhibitors. J Med Chem. 2018;61(6):2353–2371.
   PubMed Web of Science ®Google Scholar
• Ibrahim PN, Jin M; Plexxikon Inc. Synthesis of 1H-pyrrolo[2,3-b]pyrimidine derivatives that modulate kinases. WO 2016/179412 A1. 2016 Nov 10.
   Google Scholar
• Ibrahim PN, Vizor GC; Plexxikon Inc. Solid forms of a compound modulating kinases. WO 2016/179415 A1. 2016 Nov 10.
   Google Scholar
• Zhang M, Zhao B, Yu H, et al.; Abbisco Therapeutics Co Ltd. CSFlR inhibitor and manufacturing method therefore and application thereof. WO 2018/233526 A1. 2018 Dec 27.
   Google Scholar
• Zhang M, Zhao B, Yu H, et al.; Abbisco Therapeutics Co Ltd. Nitrogen heteroaryl derivative having CSF1R inhibitory activity, and preparation method therefor and application thereof. WO 2018/233527 A1. 2017 June 19.
   Google Scholar
• Hah J-M, Jung KJ; Industry-University Cooperation Foundation, Hanyang University. N-(5-arylamido-2-methylphenyl)-5-methylisoxazole-4-carboxamide derivative. WO 2016/047967 A2. 2016 Mar 31.
   Google Scholar
• Roy M, Suryavanshi H, Mukherjee A, et al.; Invictus Oncology Pvt. Ltd. Cellular signalling inhibitors, their formulations and methods thereof. WO 2017/137958 A1. 2017 Aug 17.
   Google Scholar
• Roy M, Biswas G, Suryavanshi H, et al.; Invictus Oncology Pvt. Ltd. Novel inhibitors of cellular signalling. WO 2018/146641 A1. 2018 Aug 17.
   Google Scholar
• Peng S-Z, Liao C-B, Chen H-K, et al.; Development Center for Biotechnology. Quinoxaline compounds as type III receptor tyrosine kinase inhibitors. WO 2018/071348 A1. 2018 April 19.
   Google Scholar
• Marshall AJ, Buchanan CM, Rewcastle GW, et al.; Auckland UniServices Ltd. Tricyclic heterocyclic derivatives and uses thereof. WO 2018/083635 A2. 2018 May 11.
   Google Scholar
• Kane JL, Barberis C, Czekaj M, et al.; Genzyme Corp. Colony-stimulating factor-1 receptor inhibitors. WO 2017/015267 A1. 2017 Jan 26. Preparation of nitrogen heterocycles as colony stimulating factor-1 receptor (CSF-1R) inhibitors. WO 2017/015267 A1. 2018 Jan 26.
   Google Scholar
• Feng Y, Wang R, Li J, et al.; Fijian Haixi Pharmaceuticals Co. Ltd. Heteroaryl compounds as kinase inhibitors. WO 2019/174601 A1. 2019 Oct 19.
   Google Scholar
• Qian W, Yang C, Xu G, et al.; Medshine Discovery Inc. Heterocyclic compound as CSF-1R inhibitor and use thereof. WO 2019/134662 A1. 2019 July 11.
   Google Scholar
• Jones P, Czako B, Burke J, et al.; Tesaro Inc. Small molecule inhibitors of colony stimulating factor-1 receptor (CSF-1R) and uses thereof. WO 2018/119387 A1. 2018 June 28.
   Google Scholar
• Quigley M, Smith A; Janssen Biotech Inc. Co-therapy comprising a small molecule CSF1R inhibitor and an antagonistic antibody that specifically binds CD40 for the treatment of cancer. WO 2018/160197 A1. 2018 Sep 7.
   Google Scholar
• Nam K, Kim J, Park D, et al.; Qurient Co Ltd. Quinoline derivatives as inhibitors of AXL, MER and CSF1. WO 2019/229251 A1. 2019 Dec 5.
   Google Scholar
• Wu F, Wan Z; Nanjing Transthera Biosciences Co Ltd. Novel quinoline derivative inhibitor. WO 2020/038460 A1. 2020 Feb 22.
   Google Scholar
• Cui JJ, Rogers EW, Ung J, et al.; TP Therapeutics Inc. Macrocyclic compounds and uses thereof. WO 2019/023417 A1. 2019 Jan 31.
   Google Scholar
• Liu S, Yu Z, Pang W, et al.; Adlai Nortye Biopharma Co Ltd. Highly active CSF1R compound. WO 2019/228252 A1. 2019 Dec 5.
   Google Scholar
• Bae IH, Jung SH, Ahn YG, et al.; Hanmi Pharm Co Ltd. Thieno[3,2-d]pyrimidine compound having inhibitory activity for protein kinases. WO 2019/107987. 2019 June 6.
   Google Scholar
• Quail DF, Joyce JA, Bowman RL, et al.; Memorial Sloan-Kettering Cancer Center. Compositions and methods for the treatment of glioma. WO 2016/182988 A1. 2016 Nov 17.
   Google Scholar
• Qi C, Xu J; Hutchison Medipharma Ltd. Method of treating tumors. WO 2018/090324 A1. 2018 May 24.
   Google Scholar
• Lee PA, Chantry D, Winski SL Methods and combination therapy to treat cancer. WO 2019/139583 A1. 2019 July 18.
   Google Scholar
• Park GY, Moon H-G, Timmer RT; Board of Regents of Harvard University. Methods and compositions of inhibiting CSF1R for treating allergic inflammation. WO 2019/204604 A1. 2019 Oct 24.
   Google Scholar
• Connor KM, Okuniki Y, DeYoung KJ; Massachusetts Eye and Ear Infirmary. Methods and compositions for treating autoimmune uveitis using inhibitors of colony stimulating factor 1 receptor. WO 2019/173211 A1. 2019 Sep 12.
   Google Scholar
• Mancuso R, Fryatt G, Cleal M, et al. CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. Brain. 2019;142:3243–3264.
   PubMed Web of Science ®Google Scholar
• Spangenberg E, Severson PL, Hohsfield LA, et al. Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model. Nat Commun. 2019;10:1–21.
   PubMed Web of Science ®Google Scholar
• Olmos-Alonso A, Schetters ST, Sri S, et al. Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology. Brain. 2016;139:891–907.
   PubMed Web of Science ®Google Scholar
• Sosna J, Philipp S, Albay R, et al. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer’s disease. Mol Neurodegen. 2018;13:1–11.
   PubMed Web of Science ®Google Scholar
• Bennett RE, Bryant A, Hu M, et al. Partial reduction of microglia does not affect tau pathology in aged mice. J Neuroinflammation. 2018;15:311.
   PubMed Web of Science ®Google Scholar
• Hupp S, Iliev A. CSF- 1 receptor inhibition as a highly effective tool for depletion of microglia in mixed glial cultures. J Neurosci Meth. 2019;15:332.
   Google Scholar
• Ortega-Martinez S, Palla N, Zhang X, et al. Deficits in enrichment-dependent neurogenesis and enhanced anxiety behaviors mediated by expression of Alzheimer’s disease-linked Ps1 variants are rescued by microglial depletion. J Neurosci. 2019;39(34):6766–6780.
   PubMed Web of Science ®Google Scholar
• Dorababu A. Critical evaluation of current Alzheimer’s drug discovery (2018–19) and futuristic Alzheimer drug model approach. Bioorg Chem. 2019;93:103299.
   PubMed Web of Science ®Google Scholar
• Manthey CL, Moore BA, Chen Y, et al. The CSF-1-receptor inhibitor, JNJ-40346527 reduced inflammatory macrophage recruitment to the intestinal mucosa and suppressed murine T cell mediated colitis. PLoS One. 2019;1:e0223918.
   Google Scholar
• Genovese MC, Hsia E, Belkowski SM, et al. Results from a phase IIA parallel group study of JNJ-40346527, an oral CSF-1R inhibitor, in patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug therapy. J Rheumatol. 2015;42:1752–1760.
   PubMed Web of Science ®Google Scholar
• Rauwel B, Degboe Y, Diallo K. Inhibition of osteoclastogenesis by the RNA-binding protein QKI5: a novel approach to protect from bone resorption. J Bone Miner Res. 2020;35(4):753–765.
   PubMed Web of Science ®Google Scholar
• Wang X-F, Wang Y-J, Li T-Y, et al. Colony-stimulating factor 1 receptor inhibition prevents against lipopolysaccharide-induced osteoporosis by inhibiting osteoclast formation. Biomed Pharmacother. 2019;115:108916.
   PubMed Web of Science ®Google Scholar
• Farag AK, Elkamhawy A, Londhe AM, et al. Novel LCK/FMS inhibitors based on phenoxypyrimidine scaffold as potential treatment for inflammatory disorders. Eur J Med Chem. 2017;141:657–675.
   PubMed Web of Science ®Google Scholar
• Hu X, Tang J, Hu X, et al. Imatinib inhibits CSF1R that stimulates proliferation of rheumatoid arthritis fibroblast-like synoviocytes. Clin Exp Immunol. 2019;195(2):237–250.
   PubMed Web of Science ®Google Scholar
• Guo J, Marcotte PA, McCall O, et al. Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors. Mol Cancer Ther. 2006;5:1007–1013.
   PubMed Web of Science ®Google Scholar
• Kokona D, Ebneter A, Escher PJ, et al. Colony-stimulating factor 1 receptor inhibition prevents disruption of the blood-retina barrier during chronic inflammation. Neuroinflammation. 2018;15:340.
   PubMed Web of Science ®Google Scholar
• Silver D, Wong BH; Nat. Univ. Singapore. Method for treating inflammatory complications in eye diseases. WO 2018/182527 Al. 2018 Oct 4.
   Google Scholar
• Beckmann N, Giorgetti E, Neuhaus A, et al. Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945. Acta Neuropathol Commun. 2018;6:9.
   PubMed Web of Science ®Google Scholar
• Doloff JC, Shady F, Veiseh O et al.; MIT. Methods of preventing or reducing a fibrotic response using CSF1R inhibitors. US 2019/0083495 A1. 2019 Mar 21. P. 64.
   Google Scholar
• Meziani L, Mondini M, Petit B, et al. CSF1R inhibition prevents radiation pulmonary fibrosis by depletion of interstitial macrophages. Eur Respir J. 2018;51:1702120.
   PubMed Web of Science ®Google Scholar
• Marshall D; UCB Biopharma. Method for the treatment of fibrotic disease. WO 2015/028454 A2. 2015 Mar 5.
   Google Scholar
• Xun Q, Wang Z, Hu X, et al. Small-molecule CSF1R inhibitors as anticancer agents. Curr Med Chem. 2019;26:1–23.
   Google Scholar
• El-Gamal IE, Al-Ameen SK, Mawadda G, et al. Recent advances of colony-stimulating factor‑1 receptor (CSF-1R) kinase and its inhibitors. J Med Chem. 2018;61:5450–5466.
   PubMed Web of Science ®Google Scholar